Previous Episodes Refresh
Oct 01, 2017
Don Nicholson of Nimbus: Making it RainOctober 01, 2017
Nimbus Therapeutics is in the business of building structures. Molecular yes, but corporate too — they’re unique and fit-for-purpose. CEO Don Nicholson explains it all: the partnerships, the code names, the high energy water, the bowling, the rapping. And how, at any given time, fully half of Amazon’s cloud computing power may be in use to create your next...
Aug 31, 2017
Giving it his best SchadtAugust 31, 2017
Eric Schadt may enjoy the simple things in life — high velocity, a good polo shirt — but he is the first to admit that life is not simple. Living things are such complex systems, in fact, that our best chance to promote wellness is to understand them as vast information networks. To do so, Eric is unleashing maximum scale and bringing the firepower of math to bear. He endeavors to monitor and modify...
Jul 31, 2017
Alix Lacoste: Druggable Jeopardy!July 31, 2017
Alix Lacoste crossed the ocean from France in search of new challenges, made her way to California, ran out of money and took up filmmaking in community college. Insert the windy road that led to Neurobiology degrees from Berkeley and Harvard. Today she is a subject matter expert at IBM’s internal venture: Watson. You may remember IBM Watson from such disruptions as winning Jeopardy against humans in 2011. Now it is...
Jul 01, 2017
Patently Scott KamholzJuly 01, 2017
Strong patent protection has always been a cornerstone of the biotech industry — and table stakes in a VC deal. But inter partes review has significantly changed the game in the last 5 years. Enter Scott Kamholz. Scott is once, twice, three times a doctor: Medicinae, Philosophiae, and Juris. He went from partner at a law firm, to patent judge, became a foremost expert in inter...
May 31, 2017
Joe Allen on the Bayh-otechnology IndustryMay 31, 2017
If you work in biotech, or venture capital, if you pay taxes, or take medicine… you really ought to know the name Joe Allen. He worked tirelessly behind the scenes in Washington to get the Bayh-Dole Act passed into law. Sponsored by Senators Birch Bayh and Bob Dole, and passed at the last possible opportunity in a lame...
Apr 30, 2017
Deborah Dunsire: Business XTuitionApril 30, 2017
Deborah Dunsire was a general practitioner in South Africa when a motorcycle drove her into industry. And that side trip, ultimately routing her to Boston, is still going on. She built the North American Oncology unit at Novartis, launched Gleevec, ran Millennium after the millennium, realized the value in ...
Mar 31, 2017
The Art of PappasMarch 31, 2017
Art Pappas had an extensive, international career in the pharma industry before going on to form his eponymous VC firm in the 90s. Pappas Ventures has been partnering with pharma ever since: licensing assets from them, selling portfolio companies to them, syndicating with them, and managing venture funds for them. But...
Feb 28, 2017
Stacey Seltzer on VC: Timing Timing TimingFebruary 28, 2017
If the mantra in real estate is location location location, for venture capital it might just be timing timing timing. Stacey Seltzer made the move from big pharma into venture capital during a financial crisis and has gone on to build a wildly diverse portfolio of healthcare companies at Aisling Capital. She takes us on a tour of some of the highlights, and reveals what venture capitalists do...
Jan 11, 2017
Daily Digestif featuring Marc PelletierJanuary 11, 2017
Marc was a podcaster before it was cool. That is, 2006. While producing over 100 hours of interviews on his show “Futures in Biotech” he confirmed his own future was in biotech, starting one and then another. Bypassing his jazz guitar talents and multiple black belts, he launched Aeromics out of Yale to develop the world’s 1st clinical candidate targeting a water channel for the...
Jan 10, 2017
Daily Digestif featuring Sara DemyJanuary 10, 2017
If Biotech Showcase is the farm team for JPM, then Sara Demy is the coach. She literally got high fives as her new conference burst onto the scene, bust out of its first two locations, and now boasts 400 presenting companies and 1,000 investors. And there are new offspring offerings in the Demy-Colton family as well…